Robotic Solution Simplifies and Speeds Endotoxin Detection
Lonza’s fully automated plate-based PyroTec PRO Robotic Solution accelerates endotoxin testing of parenteral pharmaceuticals.
Courtesy of Lonza
Lonza’s fully automated and integrated plate-based PyroTec PRO Robotic Solution for endotoxin testing simplifies and accelerates endotoxin testing of parenteral pharmaceuticals regardless of sample complexity.
Conventional endotoxin detection methods for parenteral pharmaceuticals involve manual data entry and template set-up steps, which can be labor-intensive and error prone. The robotic system, however, minimizes the potential for human error and the need for repeat test runs. Because it is fully automated, it captures preparation metadata, adding traceability into tracking, trending, and audit controls.
The system can be operated without any programming or scripting knowledge. Lonza’s WinKQCL Software v6.0 receives and saves the results and then transfers them into and out of laboratory information management systems or Lonza’s MODA Solution.
The platform has been designed to follow FDA’s Process Analytical Technology and Data Integrity Initiatives and to comply with the US Pharmacopeia Bacterial Endotoxin Test guidance.
Source: Lonza
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
